Conatus Pharmaceuticals Inc. (CNAT)
Symbol Info
Listed Symbol CNAT
Name Conatus Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $33,586,000
Latest Fiscal EPS $-0.59
Price Info
21 Day Moving Average $0.3374
21 Day EMA $0.348290
50 Day Moving Average $0.3265
50 Day EMA $0.394880
200 Day EMA $1.368880
200 Day Moving Average 1.230570
52 Week High $6.74
52 Week Low $0.25
52 Week Change $-91.175500
Alpha -0.016364
Beta 2.2022
Standard Deviation 0.338039
R2 0.050431
Periods 60
Share Information
10 Day Average Volume 1,413,730
20 Day Average Volume 1,009,289
30 Day Average Volume 843,751
50 Day Average Volume 989,799
Outstanding Shares 33,170,487
Float Shares 32,978,322
Percent Float 99.42%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 126
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 707,523
Institute Holdings Percent 24.900000
Institute Sold Previous 3 Months 1,505,415
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 192,165
Price Change
7 Day Price Change $0.0081000
7 Day Percent Change 2.26%
21 Day Price Change $0.0587000
21 Day Percent Change 19.03%
30 Day Price Change $0.0591000
30 Day Percent Change 19.19%
Month To Date Price Change $0.0251
Month To Date Percent 7.34%
90 Day Price Change $-0.3449
90 Day Percent Change -48.44%
Quarter To Date $0.107000
Quarter To Date Percent 41.14%
180 Day Price Change $-2.3029
180 Day Percent Change -86.25%
200 Day Price Change $-1.7529
200 Day Percent Change -82.68%
Year To Date $-1.3629
Year To Date Percent -78.78%
Profile
Description Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.
Details
Issue Type CS
Market Cap $12,176,886
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 33,170,487
CEO Steven J. Mento
Employees 31
Last Audit UQ
Classification
CIK 0001383701
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 16745 West Bernardo Drive
Suite 200
San Diego, CA 92127
Website https://www.conatuspharma.com
Facisimile +1 858 558-8920
Telephone +1 858 376-2600
Email aengbring@conatuspharma.com
Key Ratios
Profitability
EBIT Margin -41.3
EBITDA Margin -41
Pre-Tax Profit Margin -
Profit Margin Cont -42.71
Gross Margin -
Profit Margin TOT -42.71
Income Statements
Revenue $32,890,000
Revenue Per Share $0.9915
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-17,599,445
Price To Sales 0.370231
Price To Free Cash -0.4
PE High Last 5 Years -
Price To Book 0.4
Price To Cash Flow 6.7
PE Low Last 5 Years -
Price To Tangible Book 0.4
Financial Strength
Total Debt To Equity 0.0
Int Coverage -41.9
Current Ratio 3.0
Leverage Ratio 2.0
Quick Ratio 2.7
Long Term Debt To Capital -
Assets
Receivables Turnover 10.3
Invoice Turnover -
Assets Turnover 0.60
Management Effectiveness
Return Assets -27.42
Return On Equity -63.78
Return On Capital -49.28
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CNAT
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.